Kenvue Inc. (KVUE) Operating Cash Flow CAGR:18.22%(TTM)
Operating cash flow CAGR uses precomputed cash-flow statement history (cash from operations, before capital expenditures).
Over longer horizons, Kenvue Inc.'s Operating Cash Flow CAGR averages -3.39% over 3 years and -5.05% over 5 years.The TTM figure compares the trailing 12 months (sum of the latest four quarters) with the 12 months before that. Rows in the history table compare fiscal years, and the quarterly table compares single quarters; the three measure different windows and will differ. Operating cash flow CAGR measures the compound annual growth rate of the cash Kenvue Inc. generates from its core business operations, before capital expenditures, computed from rolling-twelve-month cash-flow statement history.
KVUE Operating Cash Flow CAGR Chart
Kenvue Inc. (KVUE)
KVUE Quarterly Operating Cash Flow Growth (YoY)
Operating Cash Flow growth vs the same quarter one year earlier, last 14 quarters.
KVUE Operating Cash Flow CAGR History
| Year | Start OCF | End OCF | Change | % Change | CAGR |
|---|---|---|---|---|---|
| 2025 | $1.77B | $2.20B | +$428.00M | +24.19% | +24.19% |
| 2024 | $3.17B | $1.77B | $-1.40B | -44.16% | -44.16% |
| 2023 | $2.52B | $3.17B | +$643.00M | +25.47% | +25.47% |
| 2022 | $334.00M | $2.52B | +$2.19B | +655.99% | +655.99% |
| 2021 | $3.40B | $334.00M | $-3.06B | -90.17% | -90.17% |
| 2020 | $3.00B | $3.40B | +$399.00M | +13.31% | +13.31% |
Quarterly Operating Cash Flow: QoQ & YoY
| Quarter | Value | QoQ | YoY |
|---|---|---|---|
| Q1 2026 | $489.00M | -42.7% | +14.3% |
| Q4 2025 | $854.00M | +190.5% | +7.7% |
| Q3 2025 | $294.00M | -52.7% | +18.1% |
| Q2 2025 | $621.00M | +45.1% | +41.1% |
| Q1 2025 | $428.00M | -46.0% | +49.1% |
| Q4 2024 | $793.00M | +218.5% | -16.5% |
| Q3 2024 | $249.00M | -43.4% | -63.1% |
| Q2 2024 | $440.00M | +53.3% | -40.7% |
| Q1 2024 | $287.00M | -69.8% | -64.2% |
| Q4 2023 | $950.00M | +40.9% | +47.5% |
| Q3 2023 | $674.00M | -9.2% | -8.4% |
| Q2 2023 | $742.00M | -7.5% | -8.1% |
| Q1 2023 | $802.00M | +24.5% | +137.3% |
| Q4 2023 | $644.00M | -12.5% | -36.2% |
| Q3 2022 | $736.00M | -8.8% | — |
| Q2 2022 | $807.00M | +138.8% | — |
QoQ = change vs the prior quarter; YoY = change vs the same quarter a year earlier.
About Kenvue Inc.
Kenvue Inc. functions as a global leader in the consumer health sector. The company structures its operations across three primary divisions: Self Care, Skin Health and Beauty, and Essential Health. Within the Self Care unit, it offers a diverse range of products for common conditions like coughs, colds, and allergies, in addition to pain relief, digestive health, and smoking cessation aids, featuring prominent brands such as Tylenol, Nicorette, and Zyrtec. The Skin Health and Beauty segment delivers various solutions for facial, body, hair, and sun protection, recognized under popular labels including Neutrogena, Aveeno, and OGX. Moreover, the Essential Health category provides oral hygiene, infant care, feminine wellness, and wound treatment products, marketed through esteemed brands like Listerine, Johnson's, Band-Aid, and Stayfree. Established in 2022, Kenvue Inc. maintains its corporate headquarters in Skillman, New Jersey, and operates as a subsidiary of Johnson & Johnson.
- Sector
- Consumer Defensive
- Industry
- Household & Personal Products
- CEO
- Kirk L. Perry